



PWYLLGOR STRATEGAETH A CHYNLLUNIO STRATEGY AND PLANNING COMMITTEE

DYDDIAD Y CYFARFOD: DATE OF MEETING:	30 October 2025
TEITL YR ADRODDIAD: TITLE OF REPORT:	Pharmaceutical Needs Assessment (PNA)
CYFARWYDDWR ARWEINIOL: LEAD DIRECTOR:	Jill Paterson, Director Primary Care, Community Strategy and Long-Term Care
SWYDDOG ADRODD: REPORTING OFFICER:	Rhian Bond, Assistant Director of Primary Care

Pwrpas yr Adroddiad (dewiswch fel yn addas)

Purpose of the Report (select as appropriate)

Er Gwybodaeth/For Information

ADRODDIAD SCAA

SBAR REPORT

Sefyllfa / Situation

Section 82A of the National Health Service (Wales) Act 2006 (the “2006 Act”) 1 requires each Local Health Board (LHB) to assess the pharmaceutical needs for its area and to publish a statement of its assessment and of any revised assessment. Termed a Pharmaceutical Needs Assessment (PNA), the NHS (Pharmaceutical Services) (Wales) Regulations 2020 (the 2020 Regulations) set out the minimum information that must be contained within a PNA and also outline the process that must be followed in the development of the PNA.

Cefndir / Background

In line with the NHS (Pharmaceutical Services) (Wales) Regulations 2020, Hywel Dda University Health Board (HDdUHB) developed its Pharmaceutical Needs Assessment which was published on 1 October 2021 in line with the directed timescales (Regulation 5).

[Pharmaceutical Needs Assessment - Hywel Dda University Health Board \(nhs.wales\)](https://www.nhs.uk/consult/iaopenpage/136927)

Where there is a service change, there is a requirement for the Health Board to consider whether the change has created a gap in service provision, and in line with Regulation 6(3) there is a requirement to publish a Supplementary Statement.

Regulation 6(3) makes provision for LHBs to issue supplementary statements. These should be issued where:

... there has been a change to the availability of pharmaceutical services since the publication of the PNA; this change is relevant to the granting of applications referred to in Section 83 of the 2006 Act (i.e. applications to open a new pharmacy, to relocate or to provide additional services); and the LHB is satisfied that a revised PNA would be a disproportionate response or is already in the course of publishing its next PNA, and is satisfied that immediate modification of its PNA is essential in order to prevent detriment to the provision of pharmaceutical services in its area. If there are changes either to the needs for pharmaceutical services or to the

availability of pharmaceutical services within the five-year cycle, and those changes are relevant to market entry applications, the LHB will need to consider whether or not to go through the process of revising its PNA.

However, the LHB does not need to go through that process, if to do so would be a disproportionate response to the changes. In coming to that decision on proportionality, the LHB will need to have regard to the fact that if the changes are to needs, the LHB will not have the option of a supplementary statement, but if the changes are to the availability of 2020 Regulations: Non-statutory Guidance for LHBs 24 services, the LHB will have that option.

Supplementary statements are simply a statement of fact, and do not make any assessment on the impact of the change on the need for pharmaceutical services.

Where a LHB publishes a supplementary statement, it must notify those bodies listed in regulation 7(1) as soon as is reasonably practicable (regulation 6(4)). Once issued, the supplementary statement becomes part of the PNA and so is to be taken into consideration when determining applications submitted under regulations 15 to 20 of the 2020 Regulations.

Effectively, they are an update of what the PNA says about the availability of pharmaceutical services. They are not a vehicle for updating what the PNA says about the needs for pharmaceutical services. If a LHB is in any doubt as to whether to issue a supplementary statement or to publish a revised PNA, it should seek legal advice.

Supplementary statements must be published on the LHB's website alongside the PNA (regulation 9(1)(c)). LHBs must ensure that whoever issues the supplementary statement has the delegated authority to do so.

Since the publication of the HDdUHB PNA, two supplementary statements have been issued. The first was in June 2023 following the closure of the dispensary in Solva Surgery when it became a Health Board Managed Practice on 1 April 2023 and the dispensing rights terminated with the retirement of Dr Dhaduvai. The second was in February 2024 following the closure of Superdrug, Vaughn Street, Llanelli in December 2023; both followed the Regulatory process.

Asesiad / Assessment

Regulation 6 (1)(a) places a duty on Health Boards to publish a revised PNA within the defined five-year period. In line with the development of the Health Boards Primary and Community Services strategic plan it would appear to be timely to consider bringing forward the publication of a revised PNA.

A defined timescale for the revision of the PNA has been discussed and a Steering Group has been established to provide oversight of the development of a revised PNA and its associated publication.

In reviewing and updating the current information, each Cluster will work with the Pharmacy Collaborative Lead to review the content of each Cluster chapter to ensure that the most recent information is provided in the revised document. Oversight of this work is being managed through a working group who will report into the overarching Steering Group who will have

oversight of the development of the final revised PNA. Public Health, Llais and Community Pharmacy Wales have all been invited to be members of the Steering Group.

Welsh Government has advised that the timescale for consultation remains the same for the revised document as the original.

The timescale for the work to be undertaken is set out below:

Date	Action
01.10.25	Questionnaire to be circulated to Community Pharmacy (CP) Contractors and Dispensing Practices
13.10.25	Working Group Meeting
31.10.25	Deadline for Questionnaire responses to be returned
10.11.25	Working Group Meeting - draft Carmarthenshire Cluster Reports
05.12.25	Steering Group Meeting - Carmarthenshire Cluster Reports to be signed off
19.01.26	Working Group Meeting - draft Ceredigion Cluster Reports
06.02.26	Steering Group Meeting - Ceredigion Cluster Reports to be signed off
16.02.26	Working Group Meeting - draft Pembrokeshire Cluster Reports
06.03.26	Steering Group Meeting - Pembrokeshire Cluster Reports to be signed off
16.03.26	Working Group Meeting - First draft of PNA
07.04.26	Steering Group Meeting - First draft of PNA signed off
13.04.26	Working Group Meeting
01.05.26	Consultation on draft PNA - 60 days commence
30.06.26	Consultation on draft PNA - 60 days ends
TBC - July	Working Group Meeting - Finalised draft with outcome of consultation
TBC - July	Steering Group Meeting - Finalised draft with outcome of consultation
TBC - August	Working Group Meeting
TBC - August	Steering Group Meeting
01.09.26	Draft PNA to be presented to Board (24.09.26)
01.10.26	Publish PNA

Argymhelliad / Recommendation

The Committee is asked to:

- **NOTE** the process set out to review and update the Pharmaceutical Needs assessment for Hywel Dda University Health Board and the associated timeline.

Amcanion: (rhaid cwblhau) Objectives: (must be completed)	
Cyfeirnod Cofrestr Risg Datix a Sgôr Cyfredol: Datix Risk Register Reference and Score:	3.1.15. Seek assurances on the development and delivery of the Primary Care and Community Strategic Plan.
Parthau Ansawdd: Domains of Quality Quality and Engagement Act (sharepoint.com)	7. All apply
Galluogwyr Ansawdd: Enablers of Quality: Quality and Engagement Act (sharepoint.com)	3. Data to knowledge 5. Whole systems perspective
Amcanion Strategol y BIP: UHB Strategic Objectives:	All Strategic Objectives are applicable
Amcanion Cynllunio Planning Objectives	7 Primary and community strategic plan 10 Population health
Amcanion Llesiant BIP: UHB Well-being Objectives: Hyperlink to HDdUHB Well-being Objectives Annual Report 2021-2022	9. All HDdUHB Well-being Objectives apply

Gwybodaeth Ychwanegol: Further Information:	
Ar sail tystiolaeth: Evidence Base:	The NHS (Pharmaceutical Services) (Wales) Regulations 2020
Rhestr Termiau: Glossary of Terms:	Within document
Partion / Pwyllgorau â ymgynhorwyd ymlaen llaw y Cyfarfod Bwrdd Iechyd Prifysgol: Parties / Committees consulted prior to University Health Board:	Primary Care Contract Review Group (PCCRG)

Effaith: (rhaid cwblhau) Impact: (must be completed)	
Ariannol / Gwerth am Arian: Financial / Service:	Not Applicable

Ansawdd / Gofal Claf: Quality / Patient Care:	Not Applicable
Gweithlu: Workforce:	Not Applicable
Risg: Risk:	Not Applicable
Cyfreithiol: Legal:	Not Applicable
Enw Da: Reputational:	Not Applicable
Gyfrinachedd: Privacy:	Not Applicable
Cydraddoldeb: Equality:	Not Applicable